Skip to content

Efficacy and Safety of Dexmedetomidine Added to Modified Pectoral's Block in Breast Cancer Patients

Efficacy and Safety of Dexmedetomidine Added to Modified Pectoral's Block in Patient Undergoing Breast Cancer Surgery :A Comparative Study

Status
UNKNOWN
Phases
Phase 3
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT03046238
Enrollment
60
Registered
2017-02-08
Start date
2017-02-02
Completion date
2017-04-02
Last updated
2017-02-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Breast Cancer Patients

Brief summary

To Evaluate the effect of addition of Dexmedetomedine to ultrasound guided modified Pecs block on post operative analgesia & stress response in patient undergoing modified radical mastectomy.

Detailed description

60 patients (age ≥29 years) who scheduled for modified radical mastectomy surgery under general anesthesia. Group I (Bupivacaine group): patients underwent modified radical mastectomy were given preoperative ultrasound guided modified Pecs block with 30 mL of 0.25% bupivacaine divided into 10 ml injected between the pectoralis muscles on the interfasial plane, and 20 ml injected between the Pectoralis minor muscle and the serratus muscle.Group II (Bupivacaine + Dexmedetomidine group) : preoperative ultrasound guided modified Pecs block with 30 mL of 0.25% bupivacaine plus Dexmedetomidine (1 µg/kg) divided into 20 ml injected between the pectoralis muscles on the interfasial plane , and 10 ml injected between the Pectoralis minor muscle and the serratus muscle.

Interventions

DRUGDexmedetomidine

preoperative ultrasound guided modified Pecs block with 30 mL of 0.25% bupivacaine plus Dexmedetomidine (1 µg/kg)

DRUGplacebo

preoperative ultrasound guided modified Pecs block with 30 mL of 0.25% bupivacaine

Sponsors

South Egypt Cancer Institute
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
HEALTH_SERVICES_RESEARCH
Masking
TRIPLE (Subject, Investigator, Outcomes Assessor)

Eligibility

Sex/Gender
FEMALE
Age
18 Years to 60 Years
Healthy volunteers
No

Inclusion criteria

* ASA I - II patients * weight 50- 100 kg)

Exclusion criteria

* a history of bleeding diathesis, * relevant drug allergy * opioid dependence, * sepsis, * those with psychiatric illnesses

Design outcomes

Primary

MeasureTime frameDescription
morphine consumption mg/day48 HOURSby Patient-controlled analgesia (PCA) device
Visual Analog Scale (VAS), scored from 0-1048 hourspain measurement

Secondary

MeasureTime frameDescription
first request of analgesia48 hourstime of the first request of analgesia postoperative if the VAS ≥ 3
level of stress hormones48 hourscortisol level
Adverse Events48 hoursNausea Vomiting Bradycardia Hypotension Arrhythmia Pneumothorax Vascular injury Nausea Vomiting Bradycardia Hypotension Arrhythmia Pneumothorax Vascular injury Nausea,Vomiting,Arrhythmia.Hypotension,Pneumothorax,Vascular injury andItching

Countries

Egypt

Contacts

Primary Contactmohamad F mohamad, MD
mfaroukma@gmail.com+201093942354

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026